27 September 2021 - Partner Kissei to market Tavneos in Japan, with launch expected as soon as possible following National Health Insurance price listing.

Vifor Fresenius Medical Care Renal Pharma today announced that Japan’s Ministry of Health and Labor Welfare has granted its partner, Kissei Pharmaceutical, marketing authorisation approval for Tavneos for the treatment of patients with granulomatosis with polyangiitis and microscopic polyangiitis, the two main types of ANCA associated vasculitis, a rare and severe auto-immune renal disease with high unmet medical need.

Read Vifor Fresenius Medical Care Renal Pharma press release